Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 07, 2015 1:59 PM ET

Healthcare Providers and Services

Company Overview of Clarient, Inc.

Company Overview

Clarient, Inc. provides oncology testing and diagnostic services in the United States. The company focuses on breast cancer testing, breast cancer recurrence testing, colon cancer testing, KRAS in colorectal cancer, KRAS and BRAF testing in colorectal cancer, KRAS mutation analysis, KRAS mutation testing, and pulmotype test. Its tests include ALK Rearrangement by FISH, BRAF, BRAF V600 mutation-melanoma, EGFR mutation analysis, KRAS and BRAF, KRAS mutation analysis, Mammostrat, and PI3K. The company also develops diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Its customers include pathologists, oncologists, hospitals, and biopharmaceuti...

31 Columbia

Aliso Viejo, CA 92656-1460

United States

Founded in 1993

405 Employees

Phone:

949-425-5700

Fax:

949-425-5865

Key Executives for Clarient, Inc.

Chief Executive Officer
Managing Director, Consulting Pathologist and Member of Scientific Advisory Board
Chief Financial Officer
Vice President of Global Operations
Chief Compliance Officer & Privacy Officer, General Counsel and Vice President
Compensation as of Fiscal Year 2015.

Clarient, Inc. Key Developments

Clarient and Glaxo Smith Kline to Create a Force in Cancer Testing

Clarient and Glaxo Smith Kline will create a force in cancer testing. GE Healthcare, Clarient and GSK will certify laboratories around the world to perform cancer diagnostic tests with initial network labs expected in 2015. Clarient's own laboratory expertise includes immuno histochemistry (IHC), flow cytometery, qPCR, (fluorescent) in-situ hybridization ([F]ISH), cytogenetic karyotyping, microarrays, and next-generation sequencing (NGS). Lab testing networked by GE Healthcare and Clarient will focus initially on 70 melanoma-specific mutations, including the companion diagnostics (CDx)-targeted BRAF V600E and V600K genes. Testing performed at networked labs will feed an associated data analytics service to be made available by GE Healthcare as a subscription. GSK will presumably be provided the same service to aid its activities in biopharmaceutical development. The GE-Clarient-developed lab and data analytics service will be available to clients including pharmaceutical market participants, payers and other healthcare organizations.

Similar Private Companies By Industry

Company Name Region
St. Luke's The Woodlands Hospital United States
St. Joseph Health Center United States
Focus Rehabilitation & Nursing United States
Golden State Health Centers, Inc. United States
San Miguel Hospital Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Clarient, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.